Moderna, Inc.

XTRA:0QF Stock Report

Market Cap: €17.9b

Moderna Valuation

Is 0QF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 0QF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 0QF (€45.11) is trading above our estimate of future cash flow value (€26.83)

Significantly Below Future Cash Flow Value: 0QF is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QF?

Key metric: As 0QF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0QF. This is calculated by dividing 0QF's market cap by their current revenue.
What is 0QF's PS Ratio?
PS Ratio10.7x
SalesUS$1.94b
Market CapUS$20.78b

Price to Sales Ratio vs Peers

How does 0QF's PS Ratio compare to its peers?

The above table shows the PS ratio for 0QF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average27.3x
BIO3 Biotest
1.8xn/a€1.4b
BIO3 Biotest
2xn/a€1.3b
LQ0 Dextech Medical
58.7xn/a€199.6m
HPHA Heidelberg Pharma
46.8x62.80%€142.2m
0QF Moderna
10.7x23.92%€20.8b

Price-To-Sales vs Peers: 0QF is good value based on its Price-To-Sales Ratio (10.7x) compared to the peer average (27.3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 0QF's PS Ratio compare vs other companies in the DE Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.8xn/aUS$1.63b
BIO3 Biotest
2xn/aUS$1.56b
7V0 Darwin
4x27.59%US$125.75m
2INV 2invest
2.2xn/aUS$72.74m
0QF 10.7xIndustry Avg. 7.5xNo. of Companies14PS01632486480+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0QF is expensive based on its Price-To-Sales Ratio (10.7x) compared to the European Biotechs industry average (7.6x).

Price to Sales Ratio vs Fair Ratio

What is 0QF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.7x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: 0QF is expensive based on its Price-To-Sales Ratio (10.7x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€44.71
€37.93
-15.16%
56.04%€117.03€10.40n/a20
Mar ’27€43.66
€35.74
-18.13%
58.84%€114.20€10.15n/a20
Feb ’27€37.75
€32.72
-13.32%
63.19%€113.83€14.33n/a20
Jan ’27€26.52
€31.39
+18.36%
68.96%€115.30€14.52n/a20
Dec ’26€21.00
€32.05
+52.67%
69.65%€116.29€14.64n/a19
Nov ’26€23.62
€34.96
+48.01%
84.91%€154.42€10.41n/a20
Oct ’26€24.12
€37.95
+57.33%
87.03%€169.80€12.86n/a20
Sep ’26€20.80
€38.90
+87.02%
86.64%€169.47€12.84n/a20
Aug ’26€23.61
€39.44
+67.04%
83.61%€170.99€17.27n/a21
Jul ’26€24.38
€40.37
+65.61%
80.06%€167.94€16.96n/a22
Jun ’26€23.02
€42.01
+82.49%
78.06%€174.40€17.62n/a23
May ’26€24.49
€42.44
+73.30%
75.62%€175.37€17.71n/a23
Apr ’26€26.35
€49.39
+87.49%
71.33%€195.95€23.11n/a23
Mar ’26€29.63
€54.00
+82.28%
69.21%€204.41€24.11€43.6622
Feb ’26€39.44
€60.50
+53.41%
62.51%€203.73€25.95€37.7522
Jan ’26€38.18
€70.48
+84.62%
54.74%€201.40€29.45€26.5222
Dec ’25€41.36
€72.40
+75.06%
52.44%€200.87€29.37€21.0022
Nov ’25€50.67
€84.67
+67.09%
47.38%€219.63€42.45€23.6220
Oct ’25€58.13
€90.57
+55.80%
42.80%€213.75€41.31€24.1219
Sep ’25€69.84
€112.33
+60.83%
45.98%€276.99€51.82€20.8021
Aug ’25€89.17
€129.10
+44.78%
41.41%€287.28€51.90€23.6122
Jul ’25€110.02
€136.40
+23.98%
39.17%€289.91€57.98€24.3822
Jun ’25€135.28
€130.43
-3.59%
40.27%€285.76€57.15€23.0222
May ’25€105.12
€124.72
+18.65%
43.67%€287.90€54.79€24.4922
Apr ’25€98.80
€124.32
+25.83%
42.78%€287.37€54.69€26.3523
Mar ’25€88.66
€123.06
+38.79%
42.41%€286.07€55.37€29.6324
€37.68
Fair Value
19.7% overvalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/19 18:06
End of Day Share Price 2026/03/19 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Moderna, Inc. is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Eliana MerleBarclays
Huidong WangBarclays